Navigation Links
Most Mt. Everest Deaths Occur Near Summit During Descent
Date:12/11/2008

Study says high-altitude cerebral edema is a common problem for climbers

THURSDAY, Dec. 11 (HealthDay News) -- Most deaths on Mount Everest occur during descents from the summit in the so-called "death zone" above 8,000 meters, and high-altitude cerebral edema appears to be associated with an increased risk of death.

That's the conclusion of researchers who analyzed the reported 212 deaths on the 29,000-foot mountain between 1921 and 2006.

The American, British and Canadian researchers found that the overall death rate for climbers and sherpas (locals hired to assist climbers) over those 86 years was 1.3 percent (1.6 percent among climbers and 1.1 percent among sherpas). Over the past 25 years, the death rate for climbers descending via the longer Tibetan northeast ridge was 3.4 percent, and 2.5 percent on the shorter Nepal route.

Excessive fatigue, a tendency to fall behind other climbers, and arriving at the summit later in the day were the factors most associated with risk of death, the study found. Many of those who died had symptoms such as confusion, a loss of physical coordination, and unconsciousness, all of which suggest high-altitude cerebral edema, a swelling of the brain caused by leakage of cerebral blood vessels.

Symptoms of high-altitude pulmonary edema (excessive fluid in the lungs) were rare among those who died on Everest. This surprised the researchers because high-altitude pulmonary edema is involved in most high-altitude-related deaths.

"We were also surprised at how few people died due to avalanches and ice falls in recent years... and that during descents, the mortality rate for climbers was six times that of sherpas," study leader Dr. Paul Firth, with the Massachusetts General Hospital department of anesthesia, said in a hospital news release.

The fact that fewer sherpas died during descents suggests that taking the time to acclimatize to high altitudes could im
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
2. WaterPure International, Inc. and Everest Water Ltd. Revise Payment Terms of Patent License to Produce Water From Air
3. Out of Iraq emerges hope for those with the severest of head injuries
4. Team probes why climbers die on Mount Everest
5. £5 million investment in personalized medicines to cut patient deaths
6. Injuries, Deaths Tied to Consumer Drugs Rise Sharply
7. New Report: Dangerous Drug Side Effects and Deaths Doubled Since 1998... Seniors Hit Hardest
8. Child Deaths Fall Below 10 Million For First Time
9. Climate may increase heat-related deaths by 2050s, says Mailman School of PH study
10. Montana State University researchers investigate new suspect in West Nile deaths of pelicans
11. Assisted Suicide Wont Up Deaths for Vulnerable Groups: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford 2Health News:American Kidney Fund Issues Appeal for Disaster Relief Contributions 2Health News:American Kidney Fund Issues Appeal for Disaster Relief Contributions 3Health News:SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients 2Health News:SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients 3Health News:HTH Worldwide to Provide Mobile Healthcare Tool to HRG North America's Affiliate Program 2Health News:HTH Worldwide to Provide Mobile Healthcare Tool to HRG North America's Affiliate Program 3Health News:Merck's odanacatib increased BMD over 2 years at key fracture sites in Phase IIB study 2Health News:Merck's odanacatib increased BMD over 2 years at key fracture sites in Phase IIB study 3Health News:Estrogen Cream No Match for Sun-Damaged Skin 2
Breaking Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 1National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 1Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 3Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 4Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 6Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 7Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 8Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 9Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 10
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 2Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 3Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 4